Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats

Journal of Hypertension

Volumn 23, Issue 9, 2005, Pages 1757-1770

  Cheng, Zhong Jian ^a   Grönholm, Tina ^b   Louhelainen, Marjut ^a   Finckenberg, Piet ^a   Merasto, Saara ^a   Tikkanen, Ilkka ^b   Mervaala, Eero ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c BIOMEDICUM HELSINKI   (Finland)

Author keywords

Angiotensin converting enzyme inhibitors; Cyclooxygenase; Diabetes; Endothelial dysfunction; Endothelium derived hyperpolarizing factor; Nitric oxide; Oxidative stress; Vasopeptidase inhibitors

Indexed keywords

ACETYLCHOLINE; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GLUCOSE; INSULIN; N(G) NITROARGININE METHYL ESTER; NITROPRUSSIDE SODIUM; OMAPATRILAT; PROSTAGLANDIN SYNTHASE; RENIN; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; HIGH SODIUM INTAKE; HYPERTENSION; INSULIN BLOOD LEVEL; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION; WEIGHT GAIN;

EID: 24144496154     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000179765.48324.b4     Document Type: Article

References (41)

1. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100:2153-2157.
2. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43:562-571.
3. McIntyre M, Bohr DF, Dominiczak AF. Endothelial function in hypertension: the role of superoxide anion. Hypertension 1999; 34:539-545.
4. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104:1985-1991.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
6. Graham D, Hamilton C, Beattie E, Spiers A, Dominiczak AF. Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. J Hypertens 2004; 22:329-337.
7. Intengan HD, Schiffrin EL. Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 2000; 35:1221-1225.
8. Millette E, Demeilliers B, Wu R, Laplante MA, El Midaoui A, Moreau P, et al. Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension. J Hypertens 2003; 21:125-135.
9. Pu Q, Touyz RM, Schiffrin EL. Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2002; 20:899-907.
10. Quaschning T, D'Uscio LV, Shaw S, Luscher TF. Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension 2001; 37:1108-1113.
11. Janssen U, Phillips AO, Floege J. Rodent models of nephropathy associated with type II diabetes. J Nephrol 1999; 12:159-172.
12. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 2001; 37: 433-439.
13. Cheng ZJ, Tikkanen I, Vapaatalo H, Mervaala EM. Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene. J Physiol Pharmacol 2002; 53:597-613.
14. Chiarugi A, Pitari GM, Costa R, Ferrante M, Villari L, Amico-Roxas M, et al. Effect of prolonged incubation with copper on endothelium-dependent relaxation in rat isolated aorta. Br J Pharmacol 2002; 136:1185-1193.
15. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91:2546-2551.
16. Davis BJ, Johnston CI, Burrell LM, Burns WC, Kubota E, Cao Z, et al. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 2003; 46: 961-971.
17. Bäcklund T, Palojoki E, Grönholm T, Eriksson A, Vuolteenaho O, Laine M, Tikkanen I. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo. Pharmacol Res 2001; 44:411-418.
18. Bäcklund T, Palojoki E, Saraste A, Grönholm T, Eriksson A, Lakkisto P, et al. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodelling in rat myocardial infarction. Cardiovasc Res 2003; 57:727-737.
19. Bohlen HG. Mechanisms for early microvascular injury in obesity and type II diabetes. Curr Hypertens Rep 2004; 6:60-65.
20. Dai FX, Diederich A, Skopec J, Diederich D. Diabetes-induced endothelial dysfunction in streptozotocin-treated rats: role of prostaglandin endoperoxides and free radicals. J Am Soc Nephrol 1993; 4:1327-1336.
21. 2 as an endothelium-derived contracting factor in diabetic state. Diabetes 1993; 42:1246-1252.
22. Mayhan WG, Simmons LK, Sharpe GM. Mechanism of impaired responses of cerebral arterioles during diabetes mellitus. Am J Physiol 1991; 260:H319-H326.
23. Tesfamariam B, Jakubowski JA, Cohen RA. Contraction of diabetic rabbit aorta caused by endothelium-derived PGH2-TxA2. Am J Physiol 1989; 257:H1327-H1333.
24. Koltai MZ, Hadhazy P, Posa I, Kocsis E, Winkler G, Rosen P, et al. Characteristics of coronary endothelial dysfunction in experimental diabetes. Cardiovasc Res 1997; 34:157-163.
25. Zou MH, Cohen R, Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 2004; 11:89-97.
26. Hishinuma T, Tsukamoto H, Suzuki K, Mizugaki M. Relationship between thromboxane/prostacyclin ratio and diabetic vascular complications. Prostaglandins Leukot Essent Fatty Acids 2001; 65:191-196.
27. Rapoport RM, Williams SP. Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1996; 28:64-75.
28. Hecker M. Endothelium-derived hyperpolarizing factor-fact or fiction? News Physiol Sci 2000; 15:1-5.
29. Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A. Alterations in endothelium-dependent hyperpolarization and relaxation in mesenteric arteries from streptozotocin-induced diabetic rats. Br J Pharmacol 1997; 121:1383-1391.
30. De Vriese AS, Van de Voorde J, Blom HJ, Vanhoutte PM, Verbeke M, Lameire NH. The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate. Diabetologia 2000; 43:1116-1125.
31. Coppey LJ, Gellett JS, Yorek MA. Mediation of vascular relaxation in epineurial arterioles of the sciatic nerve: effect of diabetes in type 1 and type 2 diabetic rat models. Endothelium 2003; 10:89-94.
32. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
33. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
34. Witte K, Jacke K, Stahrenberg R, Arlt G, Reitenbach I, Schilling L, et al. Dysfunction of soluble guanylyl cyclase in aorta and kidney of Goto-Kakizaki rats: influence of age and diabetic state. Nitric Oxide 2002; 6:85-95.
35. Witte K, Reitenbach I, Stolpe K, Schilling L, Kirchengast M, Lemmer B. Effects of the endothelin a receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats. J Cardiovasc Pharmacol 2003; 41:890-896.
36. Plante M, Honore JC, Neugebauer W, D'Orleans-Juste P. Endothelin-1 (1-31) induces a thiorphan-sensitive release of eicosanoids via ET(B) receptors in the guinea pig perfused lung. Clin cid (Lond) 2002; 103:1285-1315.
37. Subramanian R, MacLeod KM. Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol 2003; 477:143-152.
38. Pannirselvam M, Simon V, Verma S, Anderson T, Triggle CR. Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br J Pharmacol 2003; 140:701-706.
39. Van Buren T, Vleeming W, Krutzen MM, Van de KT, Gispen WH, De Wildt DJ. Vascular responses of isolated mesenteric resistance and basilar arteries from short- and long-term diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 1998; 358:663-670.
40. Nielsen H, Bonnema SJ, Flyvbjerg A. Effects of diabetes, insulin treatment, and osmolality on contractility of isolated rat resistance arteries. Pharmacol Toxicol 1995; 77:209-215.
41. Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the 'vulnerable' patient. Circulation 2004; 110:1926-1932.